AGT and COVID-19: In contrast to the pattern for overall RAS activity, we observed a marked increase in angiotensin 1-7 and angiotensin 1–5 levels in severe COVID-19, in line with an overall shift to the alternative RAS, independent of RAS inhibitor use (Table 2A,B, Figs. 2A,B and 4A,B).